Eisai's Partnership Initiatives

Change of licensing agreement for exclusive commercialization of the anti-obesity agent lorcaserin hydrochloride (generic name, name in the U.S. : BELVIQ®) that was originally concluded in November 2013. Based on the change in the agreement, Eisai acquired all development and marketing rights for BELVIQ® from Arena Pharmaceuticals, Inc.

License for marketing and co-promotion of the antiepileptic agent Zebinix® in Europe

Exclusive license agreement for worldwide research and development, manufacturing and sales of the anti-beta amyloid (Aβ) protofibril antibody BAN2401 for the treatment of Alzheimer's disease

• 1.
  Joint development/joint sales promotion related to BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor elenbecestat, anti-Aβ protofibril antibody BAN2401 and anti-Aβ antibody aducanumab
• 2.
  Acquisition of option rights related to joint development/joint sales promotion of the anti-tau antibody (BIIB076) under development by Biogen Inc.
• 3.
  Co-promotion of Biogen’s multiple sclerosis treatments, Avonex®, Tysabri®, and Tecfidera® in Japan to accounts that Biogen Inc. currently does not call upon, and also distribution and booking sales for three products above and Plegridy® in Asia (excluding China).

Agreement for collaborative research using JCR’s blood-brain-barrier (BBB) penetration technology J-Brain Cargo® to the discovery of new treatments

Collaboration agreement for neurological drug discovery research

Implementation of new joint research for the discovery and development of new drugs targeting dementia

License agreement for the commercialization of safinamide in Japan and Asia, currently under clinical development in Japan for the treatment of Parkinson’s disease

License agreement for worldwide development, manufacturing and sales of the antiepileptic agent Inovelon®/Banzel®

• 1.
  Comprehensive marketing agreement concerning Parkinson’s disease treatment Eldepryl® in China
• 2.
  Marketing and distribution agreement concerning Parkinson’s disease treatments Comtan® and Stalevo® in China

Co-promotion of the pain treatment Lyrica® in Japan

Agreement for global co-development and co-promotion of the dual orexin receptor antagonist lemborexant

License agreement for manufacturing and sales of the antiepileptic agent Zonegran® in Europe and Asia

Exclusive license for the development and marketing of the anti-insomnia agent Lunesta® in Japan

Comprehensive non-exclusive collaboration agreement for creating new diagnostics in the dementia area

Agreement to form major drug discovery alliance to develop new therapeutics for neurological diseases

Partnership in development and commercialization of the anticancer therapies targeting EZH2, including E7438 within Japan, as well as regarding the right of first negotiation for licensing rights in Asia

Collaboration agreement for evaluating Halaven in first-line HER2-negative advanced breast cancer in combination with Halozyme's investigational new drug PEGPH20, a PEGylated recombinant human hyaluronidase

Acquisition of exclusive license to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, the Philippines, Vietnam and Singapore

Agreement for joint development and commercialization of Eisai’s tyrosine kinase inhibitor, Lenvima®, as monotherapy and in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.’s KEYTRUDA® for multiple cancer types

Comprehensive marketing agreement concerning Orion’s breast cancer drug Fareston® in China

Joint research and development concerning CBP/β-catenin inhibitor E7386 and others

• 1.
  Exclusive license on joint development and marketing of the anticancer agent Treakisym®/Symbenda® in Japan
• 2.
  Exclusive development and marketing licenses in Singapore and South Korea

Development, sales and co-promotion of the fully human anti-TNF-α monoclonal antibody Humira® in Japan, Taiwan and South Korea (EA Pharma Co., Ltd and AbbVie GK undertake co-promotion for indications in the area of gastrointestinal disease (ulcerative colitis, Crohn’s disease and intestinal Behçet’s disease))

Agreement for integrating (absorption type split) Eisai’s gastrointestinal disease treatment business with Ajinomoto Pharmaceuticals Co., Ltd. (Establishment of EA Pharma Co., Ltd.)

License agreement concerning the development, manufacturing and marketing of the gastrointestinal prokinetic agent Cidine® in China

Exclusive rights for the development and marketing of liver disease/allergic disease agents Stronger Neo-Minophagen C® and Glycyron® Tablets in Euro-Asian countries where the products have not yet been sold, as well as exclusive first negotiation rights for exclusive marketing rights in China and other Euro-Asian countries where the products are already sold

Agreement of Sato Pharmaceutical Co., Ltd. and Eisai to co-promote new oral antifungal agent (product name: NAILIN® Capsules 100mg) containing the active ingredient fosravuconazole L-lysine ethanolate which was discovered by Eisai, in Japan

Agreement to take over the marketing authorization and marketing activities for anti-rheumatic agent KOLBET® Tablets 25mg in Japan

Agreement for industry-academia joint research for the development of new drugs for inflammatory bowel disease that use biomarkers

Exclusive licensing agreement to seek regulatory approvals and commercialize the anticancer agents Halaven® and Lenvima®, as well as antiepileptic agents Fycompa® and Inovelon® in Latin America

Strategic alliance agreements including incremental transfer of all shares of Elmed Eisai Co., Ltd., co-operation in building Eisai’s Ecosystem, as well as collaboration on the active pharmaceutical ingredient (API) business promoted primarily at Eisai’s Vizag Plant in India

Participation in a multi-stakeholder global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries

Joint research aimed at the development of new treatments for Chagas disease, malaria and tuberculosis, and development of new antimalarial medicine based on the drug targets that the joint research team identified in 2016

Joint research agreement to develop a potential new treatment for tuberculosis with the compound identified from Broad Institute’s chemical library

• 1.
  Collaboration and licensing agreement for new drug development for Chagas' disease and eumycetoma
• 2.
  Participation in the Drug Discovery Booster Consortium formed by DNDi with the aim of accelerating the discovery of new drugs for leishmaniasis and Chagas disease

Agreement for joint research and development of compounds developed by Eisai for the treatment of malaria and NTDs

Participation in public-private partnership aimed at bringing Japanese innovation to accelerate development of new medicines to cure infectious diseases in the developing world

• 1.
  Agreement for joint research for creating Wolbachia inhibitors (new antifilarial agents)
• 2.
  Agreement for joint research for developing antimalarial drugs

Participation in global partnership aimed at developing new drugs for filariasis (especially river blindness)

Agreement for joint research for the development of new antimalarial drugs

Agreement for joint research for development of new vaccines for Chagas’ disease

Alliance to find faster-acting and affordable drug regimens to fight tuberculosis

Participation in global partnership aimed at creating innovative new drugs for tuberculosis

Agreement for joint research aimed at developing new antimalarial agent

Agreement for providing free of charge DEC (diethylcarbamazine) tablets, a treatment for lymphatic filariasis, and participation in partnership for providing lymphatic filariasis diagnostic kits free of charge to endemic areas

Participation in consortium sponsored by WIPO for promoting the development of new drugs for tropical diseases